Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.43 USD
+0.07 (2.97%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.40 -0.03 (-1.23%) 7:10 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LPTX 2.43 +0.07(2.97%)
Will LPTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LPTX
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
LPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
Other News for LPTX
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Buy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic Expansion
Leap Therapeutics price target lowered by $1.50 at H.C. Wainwright, here's why
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst